Clinical Trial Update: Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing two regimens (Cisplatin, Irinotecan and Bevacizumab vs Docetaxel, Cisplatin, Irinotecan and Bevacizumab) in metastatic esophageal and ga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• PCA (Cisplatin, Irinotecan, Bevacizumab)
• TPCA (Docetaxel, Cisplatin, Irinotecan, Bevacizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-11-09